Not recruitingISRCTN97160532
SMRI-02T-162A: double blind placebo controlled trial of a protein kinase C inhibitor: tamoxifen citrate in treatment of acute mania
Research studyAges 18+Türkiye + United StatesBipolarity
Understand this study
Who could participate?
Listed age limits: from 18 years.
- Listed locations
- Türkiye · United States
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateNot clearly listed
- Recruitment status
- Not recruiting
- Enrollment listed in the registry
- Not clearly listed
- Sponsor
- The Stanley Medical Research Institute (SMRI) (USA)
- Sponsor type
- Research institute
- Study type
- Other
- Intervention type
- Other / unclear
- Locations
- United States, Türkiye
- Age range
- Over 18 Years
- Official registry ID
- ISRCTN97160532
- Official title
Show the full official title
SMRI-02T-162A: double blind placebo controlled trial of a protein kinase C inhibitor: tamoxifen citrate in treatment of acute mania
Recruitment & locations
Not recruitingThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Türkiye · United States
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is The Stanley Medical Research Institute (SMRI) (USA), a research institute.
Who can participate?
Listed age limits: from 18 years.
Is this study still recruiting?
The registry lists this study as not recruiting.
Want to explore more studies?
Explore studiesRelated studies
Effects of personalized exercise training on physical activity, health-related fitness, sleep quality, and quality of life among middle-aged and older adults with multiple health problems
Population-based Outreach Services to Reduce Homelessness among Veterans with serious mental illness (SMI)